Newsletter | February 10, 2026

02.10.26 -- Designing Drugs For Women: Closing The Therapeutic Gap

SPONSOR

Protein and antibody discovery is moving faster than ever.

Proteins, Antibodies & ADCs 2026, part of NextGen Biomed brings senior leaders together to share proven approaches for speeding discovery and improving developability. Hear Charlotte Deane (University of Oxford) on AI in protein design and learn from real case studies shaping next-gen biologics. Plus, don’t miss Comedy Night with Simon Brodkin. London | 24–25 March 2026 | Join us.

FEATURED EDITORIAL

Designing Drugs For Women: Closing The Therapeutic Gap

Women’s health remains underdeveloped in drug innovation. Growing momentum across policy, science, and funding creates an opportunity to better align drug discovery with women’s health needs.

Small Cells, Big Shifts: Recent Advances In Targeting Small Cell Lung Cancer

Therapeutic progress in small cell lung cancer has been limited, with meaningful advances emerging only in the past two years. We discuss these new developments and consider the future treatment paradigm.

INDUSTRY INSIGHTS

The Most Exciting Frontiers In Cell Therapy Development

From high-dimensional profiling to customizable Omic panels, new technologies are redefining cell therapy development—delivering better insights, efficiency, and scalability for researchers worldwide.

Everything You Need To Know About NGS

Next generation sequencing technologies and workflow automation are accelerating genomic research. Learn key differences between sequencing methods and uncover strategies to boost efficiency.

Simultaneous Spray Drying For Dry Powder Inhaler Formulations

Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.

What Are The Benefits Of Combing AI And DELs For Drug Discovery?

See how AI-powered modeling uncovers hidden patterns in DEL data, broadens chemical diversity, and accelerates decision-making to help teams prioritize compounds and move more efficiently.

Using High-Content Imaging To Drive Protein Degraders From Hit To Lead

Discover a cost-effective high-content immunofluorescence workflow using the Revvity Opera Phenix™ system to efficiently identify small molecule protein degraders with rich, multi-dimensional data.

PBPK Modeling: Mitigating Absorption Risks In Early Drug Development

Explore how PBPK models combined with in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development.

Implementing A Disaster Recovery Plan

When facing a malfunction, having an effective disaster recovery plan can make the difference between a swift fix, and losing your samples and time.

Unlock The 3 Keys To Drug Discovery Success

If you don’t know where you are going, how will you get there? Articulating the destination of your therapeutic is essential for determining whether it is commercially viable and meets required milestones.

SOLUTIONS

Your Molecule. Our Mission.

Improved Microfluidic Models With Low‑Absorption Rigid Organs